GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » No.25 Central Pharmaceutical JSC (HSTC:UPH) » Definitions » Liabilities-to-Assets

No.25 Central Pharmaceutical JSC (HSTC:UPH) Liabilities-to-Assets : 0.00 (As of . 20)


View and export this data going back to 2016. Start your Free Trial

What is No.25 Central Pharmaceutical JSC Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. No.25 Central Pharmaceutical JSC's Total Liabilities for the quarter that ended in . 20 was ₫0.00 Mil. No.25 Central Pharmaceutical JSC's Total Assets for the quarter that ended in . 20 was ₫0.00 Mil.


No.25 Central Pharmaceutical JSC Liabilities-to-Assets Historical Data

The historical data trend for No.25 Central Pharmaceutical JSC's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

No.25 Central Pharmaceutical JSC Liabilities-to-Assets Chart

No.25 Central Pharmaceutical JSC Annual Data
Trend
Liabilities-to-Assets

No.25 Central Pharmaceutical JSC Semi-Annual Data
Liabilities-to-Assets

Competitive Comparison of No.25 Central Pharmaceutical JSC's Liabilities-to-Assets

For the Drug Manufacturers - Specialty & Generic subindustry, No.25 Central Pharmaceutical JSC's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


No.25 Central Pharmaceutical JSC's Liabilities-to-Assets Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, No.25 Central Pharmaceutical JSC's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where No.25 Central Pharmaceutical JSC's Liabilities-to-Assets falls into.



No.25 Central Pharmaceutical JSC Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

No.25 Central Pharmaceutical JSC's Liabilities-to-Assets Ratio for the fiscal year that ended in . 20 is calculated as:

Liabilities-to-Assets (A: . 20 )=Total Liabilities/Total Assets
=/
=N/A

No.25 Central Pharmaceutical JSC's Liabilities-to-Assets Ratio for the quarter that ended in . 20 is calculated as

Liabilities-to-Assets (Q: . 20 )=Total Liabilities/Total Assets
=/
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


No.25 Central Pharmaceutical JSC  (HSTC:UPH) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


No.25 Central Pharmaceutical JSC Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of No.25 Central Pharmaceutical JSC's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


No.25 Central Pharmaceutical JSC Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
448B Nguyen Tat Thanh, Ward 18, District 4, Ho Chi Minh, VNM
No.25 Central Pharmaceutical JSC is engaged in the manufacturing and trading of pharmaceutical products and cosmetics. Its products comprise Rheumatin, Tribelus, Atorvastatin, and Cezirate among others.

No.25 Central Pharmaceutical JSC Headlines

No Headlines